RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.47%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$563M
AUM Growth
+$563M
(+12%)
Cap. Flow
+$42.1M
Cap. Flow
% of AUM
7.47%
Top 10 Holdings %
Top 10 Hldgs %
30.6%
Holding
102
New
10
Increased
33
Reduced
31
Closed
5
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$13.1M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$11.9M |
| 3 |
Biogen
BIIB
|
$10.2M |
| 4 |
CELG
Celgene Corp
CELG
|
$7.79M |
| 5 |
ENDP
Endo International plc
ENDP
|
$5.85M |
Top Sells
| 1 |
Alkermes
ALKS
|
$11.6M |
| 2 |
STJ
St Jude Medical
STJ
|
$9.9M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
$6.45M |
| 4 |
Labcorp
LH
|
$3.91M |
| 5 |
Perrigo
PRGO
|
$3.72M |
Sector Composition
| 1 | Healthcare | 93.53% |
| 2 | Financials | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
HCA Healthcare
HCA
$95.4B
| $7.7M | 1.37% |
100,000
-4,000
| -4% | -$308K |
|
27
Edwards Lifesciences
EW
$47.7B
| $6.98M | 1.24% |
210,000
+45,000
| +27% | +$1.5M |
|
28
Nektar Therapeutics
NKTR
$543M
| $6.69M | 1.19% |
31,333
-3,667
| -10% | -$783K |
|
29
Cardinal Health
CAH
$36B
| $6.4M | 1.14% |
82,000
-10,000
| -11% | -$780K |
|
30
Exelixis
EXEL
$9.95B
| $6.25M | 1.11% |
800,000
+150,000
| +23% | +$1.17M |
|
31
Hologic
HOLX
$14.7B
| $6.23M | 1.11% |
180,000
+120,000
| +200% | +$4.15M |
|
32
Cencora
COR
$57.2B
| $6.19M | 1.1% |
78,000
+15,000
| +24% | +$1.19M |
|
|
HZNP
33
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.09M | 1.08% |
370,000
+170,000
| +85% | +$2.8M |
|
|
34
Labcorp
LH
$22.8B
| $5.86M | 1.04% |
52,380
-34,920
| -40% | -$3.91M |
|
|
35
Alkermes
ALKS
$4.95B
| $5.86M | 1.04% |
135,599
-269,401
| -67% | -$11.6M |
|
36
Pediatrix Medical
MD
$1.45B
| $5.79M | 1.03% |
+80,000
| New | +$5.79M |
|
37
Supernus Pharmaceuticals
SUPN
$2.52B
| $5.7M | 1.01% |
280,000
+10,000
| +4% | +$204K |
|
38
McKesson
MCK
$85.9B
| $5.6M | 0.99% |
30,000
-10,000
| -25% | -$1.87M |
|
|
WBA
39
DELISTED
Walgreens Boots Alliance
WBA
| $5.44M | 0.97% |
65,300
-34,700
| -35% | -$2.89M |
|
|
ELGX
40
DELISTED
Endologix Inc
ELGX
| $5.42M | 0.96% |
43,500
| – | – |
|
41
Humana
HUM
$37.5B
| $5.4M | 0.96% |
30,000
+3,000
| +11% | +$540K |
|
42
Iovance Biotherapeutics
IOVA
$800M
| $5.27M | 0.93% |
650,000
+50,000
| +8% | +$405K |
|
43
Elevance Health
ELV
$72.4B
| $5.25M | 0.93% |
40,000
-7,000
| -15% | -$919K |
|
44
Vertex Pharmaceuticals
VRTX
$102B
| $5.16M | 0.92% |
60,000
-18,000
| -23% | -$1.55M |
|
|
MDVN
45
DELISTED
MEDIVATION, INC.
MDVN
| $4.82M | 0.86% |
80,000
-107,000
| -57% | -$6.45M |
|
|
CERN
46
DELISTED
Cerner Corp
CERN
| $4.75M | 0.84% |
81,000
-5,000
| -6% | -$293K |
|
|
ARIA
47
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $4.62M | 0.82% |
625,000
+25,000
| +4% | +$185K |
|
|
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.46M | 0.79% |
115,000
| – | – |
|
49
Omnicell
OMCL
$1.51B
| $4.4M | 0.78% |
128,537
+18,537
| +17% | +$635K |
|
|
ZLTQ
50
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $4.37M | 0.78% |
160,000
| – | – |
|